www.smh.com.au

News Store Help

Prima to present at BIO CEO & Investor Conference

Announced by: PRR
Announced on: 29/01/2013 08:54:23
          Words: 397
Status: Not market sensitive (N)
View original PDF
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au
ABN: 90 009 237 889


ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
29 January 2013
PRIMA BIOMED TO PRESENT AT THE 15
TH
ANNUAL BIO CEO & INVESTOR CONFERENCE

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
("Prima", "the Company") has announced today that Matthew Lehman, its Chief Executive
Officer, will present at the 15
th
Annual BIO CEO & Investor Conference on Tuesday, 12 February
2013 at 11:30am Eastern US Time in New York, NY. Mr. Lehman will provide an overview of the
Company and its corporate activities.

The presentation will be a live audio webcast and may be accessed by visiting Prima BioMed's
website at
. A replay of the
webcast will be available for 90 days following the presentation.


ENDS

About Prima BioMed

Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-
therapeutic products for cancer, Prima is dedicated to leveraging its current technology and
expertise to develop innovative treatment options for patients and to maximize value to
shareholders. Prima's lead product is CVacTM, an autologous dendritic cell product currently in
clinical trials for ovarian cancer patients who are in remission.

For further information please contact:

USA Investor/Media:
Ms. Jessica Brown, Prima BioMed Ltd.
+1 (919) 710-9061;

Australia Investor/Media:
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574;

Europe Investor/Media:
Mr. Axel Mühlhaus, edicto GmbH
+49 (0) 69 905505-52;
 
Back  Back to Search Results